Roche receives FDA 510(k) clearance for CoaguChek XS Pro point-of-care anticoagulation monitor

Roche Diagnostics announced today it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the CoaguChek® XS Pro system, a new point-of-care anticoagulation monitor with a built-in bar code reader that can automatically scan and capture operator and patient identification information. The bar code reader works in conjunction with the RALS®-Plus information management system to help healthcare professionals save time and prevent errors that could occur from manually entering the information for PT/INR (blood clotting time) testing with patients on warfarin therapy.

"The addition of the CoaguChek XS Pro system to the CoaguChek family of products expands the options that healthcare providers have for PT/INR testing at the point of care," said Tim Huston, director of marketing, professional diagnostics at Roche Diagnostics Corporation. "The bar code reader functionality, in particular, can help them ensure patient safety and simplify regulatory compliance, making it easier to manage an anticoagulation clinic."

The newest member of the CoaguChek XS family of meters, the CoaguChek XS Pro system requires a small sample of blood – only 8 microliters – and provides test results in about one minute. It uses built-in quality controls and offers the option to run two levels of additional liquid controls. The meter can store up to 1000 patient results and 500 optional liquid quality control results, and the operator has the option to enter comments related to either type of result.  

The CoaguChek XS Pro system also offers extensive connectivity and data management capabilities by communicating via its optional handheld base unit with the RALS-Plus information management system. The connectivity enables several reporting and device management features, including operator and QC lockout, operator and patient list management and PT/INR and QC test comment management. These features can help hospital staff streamline the regulatory compliance documentation process, capture reimbursable costs and improve their organizational efficiency.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Roche Sequencing and Life Science. (2019, June 18). Roche receives FDA 510(k) clearance for CoaguChek XS Pro point-of-care anticoagulation monitor. News-Medical. Retrieved on April 25, 2024 from https://www.news-medical.net/news/20100727/Roche-receives-FDA-510(k)-clearance-for-CoaguChek-XS-Pro-point-of-care-anticoagulation-monitor.aspx.

  • MLA

    Roche Sequencing and Life Science. "Roche receives FDA 510(k) clearance for CoaguChek XS Pro point-of-care anticoagulation monitor". News-Medical. 25 April 2024. <https://www.news-medical.net/news/20100727/Roche-receives-FDA-510(k)-clearance-for-CoaguChek-XS-Pro-point-of-care-anticoagulation-monitor.aspx>.

  • Chicago

    Roche Sequencing and Life Science. "Roche receives FDA 510(k) clearance for CoaguChek XS Pro point-of-care anticoagulation monitor". News-Medical. https://www.news-medical.net/news/20100727/Roche-receives-FDA-510(k)-clearance-for-CoaguChek-XS-Pro-point-of-care-anticoagulation-monitor.aspx. (accessed April 25, 2024).

  • Harvard

    Roche Sequencing and Life Science. 2019. Roche receives FDA 510(k) clearance for CoaguChek XS Pro point-of-care anticoagulation monitor. News-Medical, viewed 25 April 2024, https://www.news-medical.net/news/20100727/Roche-receives-FDA-510(k)-clearance-for-CoaguChek-XS-Pro-point-of-care-anticoagulation-monitor.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Roche receives Breakthrough Device Designation from FDA for new Alzheimer's disease assays